Search results for "bioinformatics"

showing 10 items of 1632 documents

Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation

2021

Each year in France, >75 000 patients receive fluoropyrimidines, including 5-fluorouracil (5-FU) and its oral prodrug capecitabine (Xeloda), to treat digestive, breast and head and neck cancers.1 Among them, ∼20% will experience severe hematological and digestive toxicities and <2% will have a fatal outcome in the first two cycles. A part of these toxicities may result from a deficiency in dihydropyrimidine dehydrogenase (DPD) which catabolizes the endogenous uracil (U) into dihydrouracil (UH2) as well as 5-FU. In 2018, French Health Authorities [Haute Autorité de Santé (HAS) and Institut National du Cancer, (INCa)] recommended the evaluation of the enzymatic activity of DPD by measuring th…

Dihydropyrimidine Dehydrogenase Deficiencybusiness.industryMEDLINEHematologyBioinformaticsmedicine.diseaseDihydropyrimidine dehydrogenase deficiencyText miningOncologyFluorouracilmedicineHumansFluorouracilbusinessLead (electronics)CapecitabineDihydrouracil Dehydrogenase (NADP)medicine.drugAnnals of Oncology
researchProduct

Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?

2020

Summary The diagnosis of Wilson disease is not always easy. For many patients, a combination of tests reflecting disturbed copper metabolism may be needed. Testing for ATP7B variants has become part of the routine diagnostic approach. The methods of genetic testing include analysis of the 21 coding exons and intronic flanking sequences, in which exons with recurrent variants would be prioritised depending on the mutation frequency in the local population. If sequencing the entire ATP7B gene cannot identify 2 variants and the suspicion for Wilson disease is high, after reviewing the clinical data, WES (whole-exome sequencing) or WGS (whole-genome sequencing) could be applied. A workflow base…

DiseaseReviewIndian childhood cirrhosisBioinformaticsDNA sequencingWES whole-exome sequencingPFIC progressive familial intrahepatic cholestasisInternal MedicinemedicineImmunology and AllergyMultiplex ligation-dependent probe amplificationWGS whole-genome sequencingExome sequencingGenetic testingWilson diseaseWhole genome sequencingWhole-genome sequencingHepatologymedicine.diagnostic_testMEDNIK syndromebusiness.industryCopper metabolismGastroenterologyMLPA multiplex ligation-dependent probe amplificationmedicine.diseaseICC Indian childhood cirrhosisNGS next-generation sequencingDMR differentially methylated regionsWhole-exome sequencingNext-generation sequencingbusinessICT idiopathic or primary copper toxicosisCDG congenital disorders of glycosylationGenetic diseasesJHEP Reports
researchProduct

Drug development for neurodegenerative diseases

2021

Drug DevelopmentDrug developmentbusiness.industryClinical BiochemistryHumansMedicineNeurodegenerative DiseasesbusinessBioinformaticsMolecular BiologyBiochemistryBiological Chemistry
researchProduct

Breakthrough pain: On the road again

2009

DrugAnesthesiology and Pain MedicineText miningbusiness.industryBreakthrough Painmedia_common.quotation_subjectMEDLINEMedicineOpioid analgesicsbusinessBioinformaticsmedia_commonEuropean Journal of Pain
researchProduct

Pathophysiology of anthracycline cardiotoxicity.

2016

Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to th…

DrugAnthracyclinemedia_common.quotation_subjectLeftanthracyclines; cancer; cardiotoxicity; Cardiology and Cardiovascular MedicineDose dependenceAntineoplastic Agents030204 cardiovascular system & hematologyanthracyclineBioinformatics03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineAntibioticsNeoplasmsVentricular DysfunctionmedicinecancerHumansGenetic Predisposition to DiseaseAnthracyclinesmedia_commonHeart FailureCardiotoxicityAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryanthracyclines cancer cardiotoxicityCancerHeartGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseaseAntineoplasticPathophysiologyCardiotoxicityCardiovascular Diseases030220 oncology & carcinogenesisHeart failureCardiology and Cardiovascular Medicinebusinessanthracyclines; cancer; cardiotoxicity; Anthracyclines; Antibiotics Antineoplastic; Cardiotoxicity; Heart Failure; Humans; Neoplasms; Ventricular Dysfunction LeftJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

2015

Drug resistance still impedes successful cancer chemotherapy. A major goal of early concepts in individualized therapy was to develop in vitro tests to predict tumors' drug responsiveness. We have developed an in vitro short-term test based on nucleic acid precursor incorporation to determine clinical drug resistance. This test detects inherent and acquired resistance in vitro and transplantable syngeneic and xenografted tumors in vivo. In several clinical trials, clinical resistance was predictable with more than 90% accuracy, while drug sensitivity was detected with less accuracy (~60%). Remarkably, clinical cross-resistance to numerous drugs (multidrug resistance, broad spectrum resistan…

DrugCancer Researchbusiness.industrymedia_common.quotation_subjectDrug resistanceBioinformaticsMultiple drug resistanceClinical trialOncologyIn vivomedicineDoxorubicinPersonalized medicinePredictive testingbusinessmedia_commonmedicine.drugFrontiers in Oncology
researchProduct

Preclinical evidence of new opioid modulators for the treatment of addiction.

2010

Addiction to opiates is one of the most severe forms of substance dependence, and despite a variety of pharmacological approaches to treat it, relapse is observed in a high percentage of subjects. New pharmacological compounds are necessary to improve the outcome of treatments and reduce adverse side effects. Moreover, drugs that act on the opioid system can also be of benefit in the treatment of alcohol or cocaine addiction. AREA COVERED BY THIS REVIEW: Recent preclinical studies of pharmacological agents for the treatment of opiate addiction (2008 to the present date).The reader will be informed of the latest drugs shown in animal models to modify dependence on opiates and the reinforcing…

DrugGABA Agentsmedia_common.quotation_subjectNarcotic AntagonistsDrug Evaluation PreclinicalReceptors Opioid muPharmacologyReceptors NicotinicBioinformaticsPharmacotherapyDopamineReceptors Opioid deltaCannabinoid Receptor ModulatorsmedicineAdrenergic alpha-2 Receptor AgonistsAnimalsPharmacology (medical)Adverse effectmedia_commonPharmacologySubstance dependencebusiness.industryAddictionReceptors Opioid kappaAntagonistGeneral Medicinemedicine.diseaseOpioid-Related DisordersRatsSubstance Withdrawal SyndromeOpioidReceptors OpioidDopamine AntagonistsFemalebusinessExcitatory Amino Acid Antagonistsmedicine.drugExpert opinion on investigational drugs
researchProduct

Preemptive analgesia-related gene and protein expression in third molar surgeries under non steroidal anti-inflammatory drug protocols : A PROSPERO-r…

2018

Background This study aimed to review translational studies focusing on third molar removal surgeries through a systematic analytical approach. Material and Methods A PROSPERO-registered systematic review (CRD42017060455) was conducted following the PRISMA statement to summarize current knowledge on gene expression in third molar surgeries. A search was performed in PubMed’s Medline and Scopus databases, without date or language restrictions, using the logical expression {[(Third molar) OR (preemptive) OR (cyclooxygenase inhibitors) OR (acute inflammation) AND (gene expression)]}. Results All studies included in the analysis evaluated gene expression in a third molar extraction model, using…

DrugGene isoformMolarmedia_common.quotation_subjectMEDLINEGene ExpressionReviewBioinformatics03 medical and health sciences0302 clinical medicineText miningGene expressionBiopsyMedicineHumans030212 general & internal medicineGeneral Dentistrymedia_commonmedicine.diagnostic_testbusiness.industryAnti-Inflammatory Agents Non-Steroidal030206 dentistry:CIENCIAS MÉDICAS [UNESCO]TransudateOtorhinolaryngologyProstaglandin-Endoperoxide SynthasesProtein BiosynthesisUNESCO::CIENCIAS MÉDICASSurgeryMolar ThirdAnalgesiaOral Surgerybusiness
researchProduct

Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?

2013

This review is part of a special issue dealing with various aspects of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). We will focus on promising treatments of NASH with antioxidants and drugs that interfere with lipid metabolism.The other therapies of interest, such as diet, behavioral changes, and insulin sensitizers are presented elsewhere. Oxidative stress is believed to play a key role in the pathogenesis of NASH and other liver diseases. Antioxidants aimed at improving chronic alcoholic or viral liver diseases have been an object of study for some time. However, only a few high quality, randomized, versus placebo-controlled, double-blinded trials hav…

DrugPathologymedicine.medical_specialtyCirrhosismedia_common.quotation_subjectDiseaseBioinformaticsAntioxidantsEzetimibeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusHyperlipidemiaDrug DiscoverymedicineHumansmedia_commonPharmacologybusiness.industryFatty livernutritional and metabolic diseasesmedicine.diseaseLipid Metabolismdigestive system diseasesFatty LiverSteatosisAntioxidantbusinessmedicine.drugHumanCurrent Pharmaceutical Design
researchProduct

Immunomodulatory drugs: Oral and systemic adverse effects

2013

Objectives: The main objectives are to present the different adverses effects of the immunomodulatory drugs that can impair the quality of life of the immunosupressed patients and study the impact of immunomodualtion on oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune functions play a central role, such as rheumatic diseases. Their effect on oral health has not been systematically investigated, however. Study Design: We review current data on the new immunomodulatory drugs from the oral health perspective based on open literature search of the topic. Results: These target specific drugs appear to have less drug interactions than earlie…

DrugPathologymedicine.medical_specialtymedia_common.quotation_subjectPlacebo-controlled studyOdontologíaReviewBioinformaticsInflammatory bowel diseaselaw.inventionImmune systemRandomized controlled triallawmedicineHumansImmunologic FactorsAdverse effectGeneral Dentistrymedia_commonOral Medicine and PathologyLupus erythematosusbusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludstomatognathic diseasesOtorhinolaryngologyRheumatoid arthritisUNESCO::CIENCIAS MÉDICASSurgeryMouth DiseasesbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct